Stock Report: () Report Updated: May 20, 2013 | Print This Page

YM BioSciences Inc., a drug development company, engages in advancing three clinical-stage hematology and cancer-related products. Its products include CYT387, a small molecule dual inhibitor of the JAK1/JAK2 kinases that is in Phase I/II clinical trial for the treatment of patients with myelofibrosis, a chronic debilitating disease; and CYT 997, an orally-available small molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and has completed a Phase II trial in glioblastoma multiforme. The company is also developing Nimotuzumab, a humanized monoclonal antibody, which is in various Phase II and III trials worldwide targeting EGFR with an enhanced side-effect profile over currently marketed EGFR-targeting antibodies. In addition, it has various preclinical research programs underway with candidates from its library of compounds identified through internal research. The company was formerly known as York Medical Inc. and changed its name to YM Biosciences Inc. in February 2001. YM BioSciences Inc. was founded in 1994 and is headquartered in Mississauga, Canada.